Soleno Therapeutics INC Form 4 insider transactions

Kristen Yen, SVP Global Clinical Operations at Soleno Therapeutics, reports transactions related to the company's merger with Neocrine Biosciences.

Soleno Therapeutics' Director Birgitte Volck reports changes in beneficial ownership following the company's merger with Neocrine Biosciences.

Soleno Therapeutics, Inc. has completed its merger with Neocrine Biosciences, Inc., resulting in changes to executive beneficial ownership of securities.

Soleno Therapeutics, Inc. announced the completion of its merger with Neocrine Biosciences, Inc., with executive Matthew Pauls reporting changes in beneficial ownership.

Soleno Therapeutics, Inc. reports on executive ownership changes following its merger with Neocrine Biosciences, Inc.

Meredith Manning, Chief Commercial Officer of Soleno Therapeutics, reports significant changes in beneficial ownership following the company's merger with Neocrine Biosciences.

Soleno Therapeutics reports on executive stock option and RSU conversions following a merger, detailing cash payouts for vested and unvested equity.

Soleno Therapeutics, Inc. has completed its merger with Neocrine Biosciences, Inc., with executives receiving cash for vested and unvested stock options and common stock.

SEC Form 4 filing reveals insider transactions for Soleno Therapeutics Inc. (SLNO) related to its merger with Neocrine Biosciences, Inc.

Soleno Therapeutics, Inc. announced the completion of its merger with Neocrine Biosciences, Inc., resulting in the conversion of restricted stock units into cash.

Soleno Therapeutics, Inc. announced the completion of its merger with Neocrine Biosciences, Inc., resulting in the cancellation of executive stock options and restricted stock units for cash.

Soleno Therapeutics, Inc. announced the completion of its merger with Neocrine Biosciences, Inc., with shareholders receiving $53.00 per share in cash.

Anish Bhatnagar, CEO of Soleno Therapeutics, reports changes in beneficial ownership following the company's merger with Neocrine Biosciences.

Solenos Chief Commercial Officer Meredith Manning sold shares to cover tax obligations related to restricted stock unit vesting.

Solenos Therapeutics' Senior VP of Clinical Development, Michael F. Huang, sold 6,582 shares of common stock to cover tax withholding obligations related to RSU vesting.

Solenos Therapeutics' Chief Financial Officer, Jennifer Fulk, acquired 39,200 restricted stock units and 67,660 stock options, signaling increased insider alignment.

Soleno Therapeutics' SVP of Global Clinical Operations and Patient Advocacy, Kristen Yen, acquired 10,400 restricted stock units and 11,900 employee stock options.

Solenos Therapeutics Chief Business Officer Kevin Norrett reported the acquisition of restricted stock units and employee stock options.

Soleno Therapeutics' Chief Commercial Officer Meredith Manning reported the acquisition of 28,600 restricted stock units and 32,800 employee stock options.

Soleno Therapeutics' Chief Financial Officer, James H. Mackaness, received grants of restricted stock units and employee stock options.

Solenos Chief Development Officer Manher Joshi reported the acquisition of restricted stock units and employee stock options as part of his compensation package.

Solenos Therapeutics' Sr. VP of Clinical Development, Michael F. Huang, received grants of restricted stock units and employee stock options.

Solenos Therapeutics' Senior VP of Regulatory Affairs, Patricia C. Hirano, received grants of 10,400 restricted stock units and 11,900 stock options.

Solenos Therapeutics CEO Anish Bhatnagar reported the acquisition of restricted stock units and stock options as part of his compensation package.

Kristen Yen, SVP of Global Clinical Operations and Patient Advocacy at Soleno Therapeutics, disposed of 904 shares of common stock to cover tax liabilities from RSU vesting.

Soleno Therapeutics' Chief Commercial Officer, Meredith Manning, reported a disposition of 1,922 common shares for tax obligations related to vested restricted stock units.

Solenos Therapeutics CFO James Mackaness reported a disposition of 2,013 shares for tax withholding related to RSU vesting on December 15, 2025.

Soleno Therapeutics' Sr. VP of Clinical Development, Michael F. Huang, reported a disposition of 812 shares for tax withholding related to RSU vesting on December 15, 2025.

Patricia C. Hirano, SVP of Regulatory Affairs at Soleno Therapeutics, sold 904 shares of common stock to cover tax obligations from RSU vesting.

Solenos Therapeutics CEO Anish Bhatnagar reported the vesting of restricted stock units, subsequent tax withholding, and a significant gift of common stock to family trusts.